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Abstract
Background: Many households in sub-Saharan Africa utilize the private sector as a primary source of treatment for
malaria episodes. Expanding access to effective treatment in private drug shops may help reduce incidence of
severe disease and mortality. This research leveraged a longitudinal survey of stocking of subsidized artemisinin
combination therapies (ACTs), an effective anti-malarial, in Accredited Drug Dispensing Outlets (ADDOs) in two
regions of Tanzania. This provided a unique opportunity to explore shop and market level determinants of product
diffusion in a developing country retail market.
Methods: 356 ADDOs in the Rukwa and Mtwara regions of Tanzania were surveyed at seven points between Feb
2011 and May 2012. Shop level audits were used to measure the availability of subsidized ACTs at each shop. Data
on market and shop level factors were collected during the survey and also extracted from GIS layers. Regression
and network based methodologies were used. Shops classified as early and late adopters, following Rogers’ model
of product diffusion, were compared. The Bass model of product diffusion was applied to determine whether shops
stocked ACTs out of a need to imitate market competitors or a desire to satisfy customer needs.
Results: Following the introduction of a subsidy for ACTs, stocking increased from 12% to nearly 80% over the
seven survey rounds. Stocking was influenced by higher numbers of proximal shops and clinics, larger customer
traffic and the presence of a licensed pharmacist. Early adopters were characterized by a larger percentage of
customers seeking care for malaria, a larger catchment and sourcing from specific wholesalers/suppliers. The Bass
model of product diffusion indicated that shops were adopting products in response to competitor behavior, rather
than customer demand.
Conclusions: Decisions to stock new pharmaceutical products in Tanzanian ADDOs are influenced by a
combination of factors related to both market competition and customer demand, but are particularly influenced
by the behavior of competing shops. Efforts to expand access to new pharmaceutical products in developing
country markets could benefit from initial targeting of high profile shops in competitive markets and wholesale
suppliers to encourage faster product diffusion across all drug retailers.
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Despite the successful development of effective medica-
tions to treat health conditions such as malaria, diarrheal
disease, HIV and tuberculosis, access to these medica-
tions remains highly constrained in most developing
countries [1]. Crowded public health facilities, drug
stock outs and lengthy travel times have all been noted
as barriers to improving access to effective medications
in public sector health facilities [2-5]. It is no wonder,
then, that the private sector is typically the first choice
in treating common health conditions such as malaria
and diarrhea [6]. A major problem, though, is that the
latest and most effective medications and technology to
conduct effective diagnoses are often unavailable at pri-
vate drug shops. Many factors likely contribute to low
availability of new drugs in retail shops. Retail prices
have been shown to impact shop level decisions to stock
particular anti-malarial medications in Kenya [7]. Re-
search has indicated that shops sometimes stock specific
medications in response to customer demands, rather
than policy recommendations [8]. Sellers’ knowledge
of pharmaceutical products and proper dosages has
been shown to be low in some contexts and could com-
promise efforts to introduce new products into retail
markets [9]. Expanding access to safe and effective
medications, along with basic diagnostics for common
conditions such as rapid diagnostic tests (RDTs) for
malaria, in privately owned drug shops might allow
households to receive proper treatment for life threat-
ening diseases earlier, reducing the chance of severe
disease and mortality.
Larger scale development of new technologies for glo-
bal health in the last decade implies that many new
health technologies will be introduced across developing
countries in the next few years [10]. Some of these tech-
nologies, such as new anti-diarrheal drugs, will sell in
the same retail markets as those used for malaria medi-
cines. It therefore becomes important to assess how
Figure 1 Models of product diffusion. top) Rogers’ original model of early to late adopters of new technologies and products bottom)
The classic Bass model of product diffusion. Innovators spearhead new products at any time, while imitators follow the example of others within
the group.
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shops are most likely to stock them first, and the impact
of different variables (such as number of employees,
number of customers, sourcing pattern and competition)
on the rate of diffusion. Understanding diffusion has
important strategic value in order to ensure the rapid
and widespread adoption of these health technologies.
Diffusion has been studied extensively in developed
country markets [11]. In his theory of the diffusion of
innovations, Rogers introduces the concept of new
“adopters.” Early adopters make use of technologies and
subsequently encourage the “late majority” and “lag-
gards” to adopt until the new technology or product
spreads through the entire market [12]. Rogers’ model
assumed that first adopters of new products differed
from people who adopt at later times. Bass, however,
expanded up Rogers work by hypothesizing that “inno-
vators” lead the introduction of new products, while
“imitators” are inspired to purchase new goods following
the example of those around them [13]. He created a
mathematical model of adoption and applied it to a
range of durable consumer goods. The interpretation of
Bass’“ innovators vs. imitators” has been since general-
ized to address marketing mechanisms of broad adver-
tising vs. social contagion. Since that time, the Bass
model has been applied extensively to determine how in-
ternal and external factors, such as within group market
competition vs. broad media messages, influence prod-
uct diffusion [14-16]. Bass’ basic ideas work well with
current social network theory, where high profile and
well-connected individuals influence proximal contacts,
who in turn imitate one another [17,18]. See Figure 1 for
a graphical representation of both the Rogers and Bass
models of product diffusion. Where the Rogers’ model
divides adopters on the basis of timing alone, the Bass
model assumes that adopters are intrinsically different
and may adopt new technologies at any time, but in dis-
tinct ways. “Innovators” will choose to adopt new tech-
nologies independently of other individuals within the
same group, while “imitators” will accept the new prod-
ucts or technologies in response to others around them.
Although much has been done to understand the
adoption and diffusion of health technologies in devel-
oped countries, little attention has been paid to this in
Sub-Saharan African countries. Even less is known for
health products which diffuse through retail markets.
Market phenomenon are driven by social, economic,
and cultural factors which vary significantly between
developed countries and low income countries in Sub-
Saharan Africa. One study, though, indicated that devel-
oping countries are known to adopt new technologies
more slowly than developed countries once available,
but that diffusion of products within countries occurs
quickly [19]. Other studies found, however, that average
penetration potential in developing countries is one
third as that of developed countries, that peak sales in
developing countries take longer than in developed
countries, and that delayed product introduction tends
to not have positive effects on the overall adoption rate
[20]. High prices have been associated with a reduced
rate of diffusion of prescription medications in develop-
ing countries [16]. Studies of pharmaceutical product
diffusion in developed country settings indicated that
large health facilities tend to lead the market in adopting
new drugs [21]. Some work on supply chains for malaria
drugs in developing countries has suggested that the
market for drugs in developing country markets is highly
complex [22], making studies of diffusion in developing
economies difficult. Of secondary interest to the authors
of this paper is how products diffuse through networks
of shops, connected either through perceived mutual
competition, or through common suppliers. A network
based approach similar to techniques used in social net-
work analyses was used to analyze competition between
shops in the study areas. Network analysis has recently
been used to study problems of social networks, such as
friend networks for information sharing or large and
intricate assemblages of partnerships as applied to the
study of sexually transmitted diseases [23-26]. Some
work has been done applying network methodologies to
economic questions [27-29]. We are unaware of any
work that has been done that analyzes network based
competition to understand stocking behavior of certain
goods and/or pricing.
Knowing how and whether existing models of product
diffusion can be applied to drug shops and private mar-
kets in sub-Saharan Africa could help public health
groups more effectively expand access to essential medi-
cations. By identifying specific characteristics of early
adopters, new drugs may be introduced more efficiently
into the market, thus maximizing availability and min-
imizing time to universal adoption. We hypothesize that
stocking of new products will be the result of a combin-
ation of factors which include both local demand for ef-
fective products, and a desire for shops to remain
competitive in the market by emulating the behavior of
peer shops.
In this paper, we leveraged data from a study which lon-
gitudinally tracked the adoption of artimisinin combin-
ation therapies (ACTs), an effective anti-malarial drug, in
Tanzanian Accredited Drug Dispensing Outlets (ADDOs).
ADDOs are the lowest level of drug shops that currently
have approval from the Tanzania Food and Drug Author-
ity (TFDA) to sell formal anti-malarial medications such
as ACTs. The ADDO system was created to improve ac-
cess to affordable medicines and services in retail pharma-
ceutical outlets in underserved rural and peri-urban areas
[30]. The study was conducted as a part of an operational
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ity – Malaria (AMFm), an ACT subsidy program hosted
by the Global Fund to Fight Tuberculosis, HIV and Mal-
aria. The AMFm provided a supply side subsidy to reduce
prices and to increase availability of ACTs in private drug
shops in eight pilot countries. Data were collected close to
when AMFm subsidized ACTs first became available to
ADDOs in Tanzania. Prior to our study, ACTs were pro-
hibitively expensive and generally unavailable in private
drug shops [31]. We emphasize that studies of product
diffusion usually model the pattern of adoption of new
technologies or products into a particular market. At the
time of our study, however, ACTs had already been avail-
able in the public clinics and hospitals and thus not new
to Tanzania. High prices of ACTs, however, heavily con-
strained availability in private sector outlets, confirmed by
the initial round of our survey (see Results). Given our
focus on a specific class of private sector drug outlets
(ADDOs), the near unavailability of ACTs in these shops
and the presence of competing anti-malarial medications,
we feel that models of product diffusion as presented in
this paper are relevant and applicable. Though the pat-
terns of diffusion and characteristics of early and late
adoption might be different for an entirely new product to
Tanzania, we feel that this data set offers a unique oppor-
tunity to follow a specific product (low cost ACTs) from
time of introduction in a specific and important pharma-
ceutical sector (ADDOs).
This paper will be structured as follows. First, we will
describe patterns of ACT stocking over time. Second, we
will test associations of competition and demand vari-
ables with ACT stocking over the study period. Third,
we will characterize shops as early and late adopters and
test associations of possible determinants with adopter
status. Finally, we will measure and test the contribu-
tions of internal and external influence using a mixed in-
fluence model. A broad goal of this paper will be to
discover whether new product adoption in ADDOs is
the result of a shop level motivation to stock ACTs due
to actual or yet to be realized customer demand (innov-
ator), or whether shops stock new products due to influ-
ence by market competitors.
Methods
Ethical approval
The study was approved by the Institutional Review
Board of Harvard University School of Public Health
(Protocol #19372-102) and the National Institute of
Medical Research of Tanzania (NIMR/HQ /R.8a/Vol.
IX/1017).
Data
Two remote, malaria endemic regions of Tanzania
(Mtwara and Rukwa) were selected for inclusion in this
study in consultation with Tanzania’s Malaria Control
Program (NMCP). A complete census of ADDOs was
conducted in both regions. Shops were included in the
study, contingent upon the availability and verbally con-
firmed consent of the shop owner and/or dispenser.
Over 97% of shops in Mtwara and 99% of shops in
Rukwa consented to participate. Community members
in one location accused survey teams of practicing
witchcraft forcing one shop to drop out of the study. In
total, 356 shops were included. (see Figure 2). Data were
collected from February 2011 to May 2012 over seven
survey periods (see Table 1). Though the first shipment
of AMFm ACTs arrived in Tanzania in November 2010
[32], distribution in the private sector did not occur until
several weeks later. The beginning of the survey was
timed to assess AMFm ACT stocking within a short
time of having been first ordered by shops from sup-
pliers. Surveyors noted whether AMFm co-paid ACTs
were being stocked on the day of the survey (confirmed
by noting the presence of a specialized ACT leaf logo
printed on the packaging) and recorded retail prices. For
the purposes of this research, “ACT” will refer to ACTs
distributed under the AMFm and “ACT stocking” will
refer the presence of absence of AMFm labelled ACT
products. Comprehensive retail audits, where a full in-
ventory of all anti-malarial products was performed,
were administered twice during the study period. At the
final comprehensive audit, shop attendants were asked a
set of questions regarding sources of supply, stocking
frequency, restocking amounts and other questions re-
garding the business. Though not included in this study,
the presence or absence of other essential medications
was noted during the comprehensive retail audit.
Measurement
Shop level characteristics were assessed using character-
istics related to demand, competition, and shop staffing,
sourcing and ordering.
Demand measures
Demand side characteristics were assessed through a
combination of methods. The size of shops’ customer
base and possible catchment populations were estimated
using data from the survey and available GIS layers.
AfriPop has created interpolated grid maps of popula-
tion for nearly all sub-Saharan African countries using
available census data, and satellite imagery [33]. To esti-
mate catchment populations of each ADDO, a radius of
5 km was drawn around the known location of each
shop. Total population within 5 km of each shop was ex-
trapolated from the AfriPop population raster for
Tanzania and added to the database. When estimating
catchments, it was assumed that customers would travel
no more than 5 km to obtain goods, but could choose
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erences was not available, no attempt was made to deter-
mine shops of choice. Of interest, rather, was the size of
the potential customer base available to each shop. Catch-
ments, particularly in urban areas, could overlap. In
addition to population based demand estimates the shop
attendants were asked to provide an estimate the number
of customers that visited their shop on the previous day,
the number of customers that presented to buy drugs for
malaria-like conditions, and the number of customers on
busy and slow days.
Competition measures
Retail competition was analyzed using two methods.
First, we utilized a spatial methodology assuming that
proximity to other shops implies competition for cus-
tomers in overlapping catchments [5]. For each shop in
the survey, using the exact locations, we calculated the
Table 1 Data collection schedule
2011 2012
Retail Audits mid Feb to
end Mar 2011
end Mar to
mid Apr 2011
end Apr to
mid May 2011
Aug 2011 Jan 2012 end Mar-mid
Apr, 2012
May 2012
R1 R2 R3 R4 R5 R6 R7
Comprehensive Audit Comprehensive Audit
Figure 2 Locations of surveyed ADDOs and target regions.
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within 3 km. We performed the same procedure using
the locations of known public health facilities offering
reproductive and child health (RCH) services
a.
ADDO representatives were asked to provide the names
of up to three other drug shops which they regarded as
their competitors. The names were compared with the
master list of participating ADDOs in this study and nu-
merical shop keys were assigned for consistency. We con-
structed a “competition network” of all shops, graphically
illustrating the connections between shops. Certain shops
may maintain a high level of prominence within the mar-
ket through having a large market share, the ability to sell
products for considerably lower prices than other shops or
other factors. Thus, these shops may be more likely to be
identified by shops as competitors than other shops, even
when distant. Similarly, two shops may be connected to
one another through a mutual intermediary, but might be
unaware that they are identifying a common competitor.
Two basic measures of network centrality were applied in
this case: degree centrality and betweenness. For each shop,
the degree is the number of other shops that identify that
shop as a market competitor. Betweenness is a measure of
whether a specific shop acts as a bridge between otherwise
disconnected shops in the network. Calculation of the net-
work measures was performed using UCINETver. 6 [34].
Shop staff and stocking habits
Shops were asked to report the qualifications of dis-
pensers, their level of health training and the number of
employees in the shop. Shops were also asked to report
the quantity and frequency of replenishment, and the
source of obtaining supplies (location of wholesaler).
Product diffusion under the AMFm
Using Rogers’ (8) methodology, shops were classified
into the broad categories of “early adopters” and “late
adopters.” This was done through visual inspection of
stocking trends. Finer classifications (e.g. “mid to late
adopters” and “laggards”) would have been ideal, but it
was thought that the small number of survey rounds
would not accommodate them.
Coefficients of innovation (internal influence) and imi-
tation (external influence) were produced using a form
of the classic Bass diffusion model [13]. The version of
the Bass model to describe sales of new products used in
this paper is:
St ðÞ¼
e− pþq ðÞ t
1 þ
q
pe− pþq ðÞ tÞ
2

where S(t) is the rate of change of adoption (at time t)
p and q are the coefficients of innovation (the propen-
sity for shops to stock products independent of other
shops) and imitation (the propensity for shops
to stock products in response to the behavior of peer
shops). Parameters were estimated using a non-linear
regression methodology [35]. Through these estimates,
we hope to quantify the potential roles of shops which
indep1endently assume risks of stocking new and un-
tested retail products (innovation) and those which
stock as a result of a need to imitate other shops (imi-
tation or social contagion [36]). If p/q ratio, for ex-
ample, were larger than 1, we might conclude that
shops stock ACTs due to endogenous market imitation
and a desire to remain competitive, rather than to
broad messages sent through either exogenous adver-
tising avenues, messages from common wholesale sup-
pliers or customer demand. The small number of time
points prevented the implementation of more rigorous
forms of diffusion modeling (e.g. a hazard model with
predictive covariates).
Regression methods/tests of association
Tests for associations of all variables with ACT stocking
over the seven survey rounds were performed using a lo-
gistic regression model including covariates for survey
round and region to account for trend and differences
between the two survey areas. We conducted tests for
associations of all variables with ACT stocking, and with
early/late adopter status. As ACT stocking is likely the
result of a combination of factors, some of which may
be correlated with one another, a multivariate model of
ACT stocking was produced. Backwards selection (based
on Akaike’s Information Criterion (AIC)) was used to se-
lect an optimal subset set of covariates from all available
variables. Variables were eliminated one by one, in order
of highest p-value, until a final set of significant covari-
ates which minimized the AIC was reached. Associations
of potentially predictive covariates and adopter status
were tested using chi-square tests for categorical vari-
ables and t-tests for continuous variables. All statistical
analyses were performed using R version 2.12.0 [37].
Results
Descriptive results
Descriptive results can be found in Table 2.
Customer demand
There was an average of approximately 12,000 people
living around each ADDO, though catchment popula-
tions varied widely (Min:63: Max: 37,241). Shops re-
ported a mean number of 25 customers the previous
day, 4.5 of which appeared for malaria. Out of all cus-
tomers seen the previous day, an average of 20% of them
appeared with malaria-like symptoms.
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Distances between shops ranged from .1 km to nearly
40km between each shop, with a mean distance of ap-
proximately 3 km. There number of shops located
within a 3 km radius around each shop ranged from
zero to a maximum of 36 shops. Similarly, ADDOs were
located proximally to public RCH clinics, with distances
ranging from less than 30 meters to nearly 130 km away.
Shops were asked to name up to three other shops
that were seen as market competitors. Not all shops
Table 2 Descriptive results of ADDO survey: shop level characteristics
Mean/%
N 356
Competition
Distance to Nearest ADDO 3.17 (Range:.10,38.89)
Number of ADDOs Within 3km 8.58 (Range:.0, 35)
Distance to Nearest RCH Clinic 2.23 (Range: .02, 130.4)
Number of RCH Clinics Within 5km 1.85 (Range: 0, 7)
Degree 2.37
Betweenness 7.62
Demand
Population Within 5km 12090
Number of Customers on Previous Day 25.05
Number of Customers Presenting for Malaria on Previous Day 4.56
Percent Customers Presenting for Malaria 19.79%
Supply
Frequency of Ordering
Every Week 5.58%
Twice a month 29.88%
Once a month 43.43%
Every Two Months 11.16%
Every Three Months 7.97%
Don’t Know/No Set Schedule 1.99%
Amount Ordered
1 week 3.59%
2 weeks 28.69%
1 month 45.02%
2 months 12.35%
3 months 6.77%
Don’t Know 3.59%
Supplier Location
Dar Es Salaam 9.16%
Masasi town 5.58%
Mbeya 10.36%
Mtwara town 25.10%
Sumbawanga 49.80%
Qualifications
Doctor Present 12.20%
Pharmacist Present 1.65%
Nurse or Midwife Present 65.02%
Means are presented for ordinal and continuous variables. Percentages are presented for categorical variables.
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ported three competitors as requested, though some re-
ported less. 89% of shops identified at least one
competitor. 67% identified at least two, whereas only
44% reported three. From this we were able to con-
struct the network of competing shops and common
suppliers (See Figure 3). The mean network degree,
or the number of times each shop was named by an-
other, was 2.37 and the average betweenness centrality,
a measure of network connectivity, was 7.62. The most
highly connected shop had 11 connections and the low-
est had 0.
Shop level ordering practices
Most shops (43%) reported restocking medicinal sup-
plies once a month. Another 30% order stock biweekly
and 12% of shops order stocks once every two months.
Few shops ordered stocks weekly and even fewer or-
dered once every 3 or more months. Upon restocking,
most shops reported ordering a month’s supply of drugs
or less. Shops generally ordered from proximal whole-
salers in nearby mid-sized towns, though nearly 10% re-
ported ordering stocks from distant Dar es Salaam.
There was a nurse/midwife present at nearly two thirds
of the shops. A few reported having a doctor or a
pharmacist on duty.
Diffusion of ACTs under the AMFm
Stocking of AMFm subsidized ACTs increased rapidly
over the seven survey rounds. 12% of shops were reported
to have ACTs in stock in the first round. By the final
round, more than 80% of shops were stocking ACTs. Pat-
terns of stocking over time were similar between Rukwa
and Mtwara, but shops in Mtwara were more likely to
stock ACTs overall. (See Figure 4 and Table 3).
Determinants of ACT stocking
Logistic regression models controlling for survey round
and region indicated that the number of ADDOs (OR
1.02 (1.01, 1.03)) and RCH clinics within a 3 km radius
(OR 1.06 (1.00, 1.12)) were both associated with in-
creased odds of stocking ACTs over the seven survey
rounds. Spatial proximity to other ADDOs (OR 1.00
(0.99, 1.00)) and RCH clinics (OR 1.00 (0.98, 1.01)) was
not associated with ACT stocking.
While the association of increased population with
ACT stocking was not significant (OR 1.01 (0.99,1.02)),
increased numbers of customers appearing on the
previous day (OR 1.02 (1.00,1.03)) and increased num-
bers of customers presenting for malaria concerns (OR
1.07 (1.04,1.09)) were both predictive of ACT stocking
in any round. The fraction of customers presenting for
malaria concerns was highly predictive of ACT stocking
(OR 3.01 (1.41, 6.46)). Frequency of ordering and
supplier location was found not to be associated with
ACT stocking. Though the number of shops which had
ap h a r m a c i s to nd u t yw a ss m a l l ,t h eo d d so fA C T
stocking in shops which employed one were more than
three times higher than those which did not when con-
trolling for survey round and region. See Table 4 for
complete results.
Shops were asked to list up to three of their perceived
competitors. A logistic regression model for ACT stock-
ing was produced testing associations with the stocking
status of perceived competitors while controlling for sur-
vey round and region. Tests indicated that the odds of
stocking ACTs for shops where one or more named
competitors also stocked them were 1.51 (CI: 1.17, 1.95)
times higher than shops whose competitors did not
stock ACTs. Increasing network degree of shops was
highly associated with increased odds of ACT stocking
Figure 3 Network of competing shops and common suppliers. Sizes of nodes are proportional to network degree.
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tically associated with ACT stocking (OR 1.01 (1.00,
1.01)), though the effect was weak.
As the relationship between predictors and outcomes
may not be entirely linear, patterns of association of pre-
dictors on ACT stocking were explored graphically.
Smoothed estimates of predictive covariates controlling
for survey round and region can be seen in Figure 5.
Population, percent of customers presenting for malaria
concerns, number of shops within 3km, and total cus-
tomers on the day of survey were all positively and
mostly linearly associated with ACT stocking. Distance
to nearest shop was inversely associated with ACT
stocking for shops which were very proximal to one an-
other (under 10 km), but not associated at all for very
isolated shops. Network degree showed positive associa-
tions with ACT stocking.
Multivariate model of ACT stocking
All variables from Table 4 and the variable of ACT
stocking by one or more named competitors were con-
sidered for the model. The final model, produced
through a backward selection procedure using AIC, is
presented in Table 5. Controlling for region and survey
round, the number of customers on the previous day
and the fraction of customers appearing for malaria con-
cerns were both positively associated with ACT stocking.
Increased numbers of proximal shops was associated
with a statistically significant increase in the likelihood
of stocking ACTs. Larger numbers of proximal RCH
clinics was associated with a decreased likelihood of
stocking ACTs. In short, ACT stocking appeared to be
associated with a combination of shop traffic and the
presence of proximal competitors.
Early/late adopters
Shops which first stocked ACTs in any of the first two
survey rounds were considered “early adopters” while all
other shops were classified as “late adopters.” Though
there was evidence that some measures were associated
with the probability of stocking in any round, very few
of our measures were associated with early vs. late
adopter status. Early adopters, however, tended to be lo-
cated in areas of higher population than that of late
adopters. The fraction of customers presenting for mal-
aria concerns was also slightly higher in early adopting
shops compared to shops which started stocking ACTs
at a later time (24% vs. 18%). The location of the whole-
sale supplier was significantly associated early adoption
of ACTs. More than half of shops which first stocked
ACTs within the first three rounds reported buying their
supplies from a wholesale supplier in Mtwara perhaps
indicating that this particular supplier offered subsidized
ACTs ahead of other wholesalers. Full results can be
seen in Table 6.
Graphically, we sought to characterize adopter status
by population, distance to nearest competing shop, and
the number of shops within a 3km radius (see Figure 6).
Figure 4 ACT product diffusion over the seven survey round under the AMFm. a) Trends by the two survey regions (Rukwa and Mtwara)
along with overall trends are plotted. Early adopters are designated as those shops which stocked ACTs in the first two survey periods. All other
are classified as mid-to-late adopters. b) Bass model of ACT diffusion estimated through non-linear methods.
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tomers appearing for malaria concerns was associated
with an increased probability of being an early adopter.
Distance to nearest competing shops was only relevant
for shops where the closest shop was within 5km. Past
5km, there appeared to be no association with adopter
status. Increased numbers of proximal shops (within a
3km radius) was associated with an increased probability
of being an early adopter. However, shops located within
very dense and competitive areas appeared to have the
lowest probability of stocking ACTs under this program.
Internal vs. external influence
Again, the small number of time points constrained our
ability to estimate coefficients of internal and external
influence through more complex models. However,
using the previously presented model form, parameters
estimates for the Bass model were p=.01, q=.53 yielding
a p/q ratio of 53. Shops may be responding to broader
market trends (imitative behavior) when making deci-
sions to stock ACTs, as opposed to a desire to satisfy
local demand.
Discussion
An operational research study of the AMFm provided us
with an opportunity to track the diffusion of a health
product in the private market in a developing country
from its introduction to widespread availability. We know
of no other study which has focused on the question of
how pharmaceutical products diffuse in developing world
markets using a comprehensive longitudinal series of sur-
veys. Understanding the specific characteristics of shops
which stock new products and shops which adopt new
products earlier than others could help inform targeting
and design of future campaigns to increase availability.
Through our study, we found that busier, more prom-
inent shops in direct competition with others in densely
populated areas were more likely to stock ACTs than
isolated shops which served fewer customers. Another
study also found that shops proximal to outlets which
also sold ACTs were more likely to stock them, confirm-
ing that shop level competition is a factor in the stocking
of new medicinal products [38]. We also found evidence
that might suggest that shops which have a higher
fraction of their customers presenting for malaria con-
cerns are more likely to stock anti-malarial medications
overall and are more likely to adopt new products tar-
geting malaria more quickly. We noted that a specific
wholesaler location (Mtwara) was associated with early
product availability in small shops suggesting that
wholesalers also may play an important role in expand-
ing product availability. Though the limited number of
time points prevented more rigorous analysis using a
mixed influence model, the parameters estimates from
the Bass model used suggest that shops predominantly
imitate one another when stocking ACTs, rather than re-
spond exclusively to customer demands. This result is to
be expected if shops are responding to suggestions from
wholesalers to stock new products. An optimal multi-
variate model included a combination of increased cus-
tomer demand, both overall and for malaria, and
increased numbers of proximal sources of pharmaceut-
ical goods. This could imply that decisions to stock new
products are the result of a complex mix of factors re-
lated to both a need to imitate and thus remain competi-
tive in the market and to simultaneously satisfy the
potential demands of customers. More work needs to be
done to parse out the relative impacts of competition
and demand factors in influencing shop level decisions
to stock new products.
Our study suffered from many limitations. First, the
ability to generalize our results to other regions of
Tanzania and to other Sub Saharan African countries
may be limited. Rukwa and Mtwara respectively repre-
sent inland and coastal areas of Tanzania in terms of ac-
cess to public and private health care. The results might
differ in the area surrounding heavily urbanized Dar es
Salaam. Follow up research might include urbanized Dar
es Salaam to determine whether patterns of diffusion dif-
fer from those in other, more remote regions. Further,
presence of the shop accreditation system in Tanzania
might limit the ability to generalize our findings to other
African countries. Though private, the ADDOs are li-
censed and accountable to the central regulatory body
which, in cooperation with local health authorities and
development partners, attempts to ensure standards of
shop keeper knowledge and product quality. The private
pharmaceutical sector in other Sub Saharan African
countries might not be as formalized. Future research
might attempt to monitor patterns of diffusion of new
pharmaceutical products in private sector health markets
in a number of countries simultaneously.
Table 3 Percent of shops stocking AMFm co-paid ACTs by survey round and region
R1 R2 R3 R4 R5 R6 R7
Both Regions 12.55% 26.09% 37.55% 66.67% 73.25% 78.14% 80.08%
Rukwa 3.45% 7.64% 19.26% 51.82% 62.41% 70.14% 73.38%
Mtwara 24.55% 50.46% 61.76% 87.63% 88.24% 89.32% 88.78%
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shop locations, names of competing shops and customer
numbers, we lacked more detailed knowledge of the
attitudes and experiences of the shop proprietors
themselves. Informal interviews while study teams were
in Tanzania indicated that business knowledge and atti-
tudes were heterogeneous among shops. Future studies
might seek to collect more detailed data on how shop
Table 4 Odds ratios and confidence intervals for bivariate associations of shop level characteristics with AMFm co-paid
ACT stocking controlling for trend over the seven survey rounds and survey region
OR (95% CI) p
Competition
Distance to Nearest ADDO 1.00 (0.99,1.00) 0.23
Number of ADDOs Within 3km 1.02 (1.01,1.03) 0.001
Distance to Nearest RCH Clinic 1.00 (0.98,1.01) 0.90
Number of RCH Clinics Within 3km 1.06 (1.00,1.12) 0.04
ACT Stocking by one or more named competitors 1.51 (1.17, 1.95) .002
Degree 1.16 (1.08,1.25) <.0001
Betweenness 1.01 (1.00,1.01) 0.01
Demand
Population Within 5km 1.01 (0.99,1.02) 0.31
Number of Customers on Previous Day 1.02 (1.00,1.03) <.0001
Number of Customers Presenting for Malaria on Previous Day 1.07 (1.04,1.09) <.0001
Percent Customers Presenting for Malaria 3.01 (1.41,6.46) 0.004
Supply
Frequency of Ordering
Every Week
Once a month 1.01 (0.59,1.73) 0.96
Twice a month 1.13 (0.65,1.96) 0.66
Every Two Months 0.89 (0.48,1.65) 0.70
Every Three Months 0.65 (0.33,1.28) 0.21
Don’t Know/No Set Schedule 1.85 (0.72,4.77) 0.20
Amount Ordered
1 week
2 weeks 0.71 (0.37,1.38) 0.31
1 month 0.69 (0.36,1.32) 0.26
2 months 0.70 (0.35,1.43) 0.33
3 months 0.33 (0.15,0.74) 0.01
Don’t Know 0.59 (0.25,1.40) 0.23
Supplier Location
Dar Es Salaam
Masasi town 0.88 (0.45,1.74) 0.71
Mbeya 1.93 (0.92,4.06) 0.08
Mtwara town 1.54 (0.93,2.53) 0.09
Sumbawanga 1.22 (0.64,2.33) 0.55
Qualifications
Doctor Present 1.06 (0.76,1.48) 0.74
Pharmacist Present 3.12 (1.29,7.53) 0.01
Nurse or Midwife Present 1.20 (0.91,1.60) 0.20
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http://www.biomedcentral.com/1472-6963/13/526Figure 5 Plots of smoothed estimates of predictive covariates on the log odds of stocking AMFm ACTs controlling for survey round
and region. a) population, b) percent of customers presenting for malaria concerns, c) total customers the previous day, d) distance to nearest
shop, e) number of shops within a 3km radius and f) network degree.
Table 5 Results of optimal multivariate model based on a backward selection procedure
OR (95% CI) p
(Intercept) 0.14 (0.09, 0.24) <.0001
Total number of customers on previous day 1.02 (1.01, 1.02) <.0002
Percentage of customers appearing for malaria concerns (per 10% increase) 1.19 (0.52, 2.70) <.0003
Number of ADDOs within 3km radius 1.04 (1.02, 1.07) 0.001
Number of RCH clinics within 3 km 0.89 (0.78, 1.01) 0.065
Round 1 Ref
Round 2 2.72 (1.61, 4.61) <.0001
Round 3 4.99 (2.96, 8.43) <.0001
Round 4 22.55 (13.07, 38.90) <.0001
Round 5 28.41 (16.40, 49.21) <.0001
Round 5 41.73 (23.78, 73.24) <.0001
Round 7 49.06 (27.58, 87.26) <.0001
Mtwara Ref
Rukwa 0.15 (0.11, 0.20) <.0001
All variables presented previously were included in the model, and then removed one by one in order of highest p-value until an optimal set of significant
variables (with minimum AIC) was reached.
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at all. Knowing more information about what criteria
shop owners use to determine which new products will
they start stocking might help create efficient strategies
for the launch and faster adoption of new health tech-
nologies in private markets. There is evidence that
educational strategies that seek to improve the know-
ledge and thus efficiency of small drug providers has
been shown to be effective in some contexts [39].
Third, the unique nature of the AMFm might have
produced a case of product diffusion that may not al-
ways be applicable to other contexts. New products that
Table 6 Associations of shop level characteristics with early and late adopters of AMFm ACTs with tests for statistical
differences
Early Adopter Mid/Late Adopters p
Competition
Distance to Nearest ADDO 2.65 5.43 0.23
Number of ADDOs Within 3km 7.76 9.41 0.22
Distance to Nearest RCH Clinic 1.55 2.79 0.18
Number of RCH Clinics Within 3km 1.57 1.95 0.16
Degree 2.38 2.42 0.86
Betweenness 9.36 7.21 0.57
Demand
Population Within 5km 15238.84 11984.37 0.02
Number of Customers on Previous Day 28.36 24.76 0.41
Number of Customers Presenting for Malaria on Previous Day 5.38 4.38 0.19
Percent Customers Presenting for Malaria 0.24 0.18 0.01
Supply
Frequency of Ordering 0.68
Every Week 4.05% 6.85%
Once a month 47.30% 38.36%
Twice a month 29.73% 30.14%
Every Two Months 8.11% 13.01%
Every Three Months 9.46% 8.90%
Don’t Know/No Set Schedule 1.35% 2.74%
Amount Ordered 0.3
1 week 1.35% 4.79%
2 weeks 28.38% 26.71%
1 month 52.70% 41.10%
2 months 9.46% 13.70%
3 months 6.76% 8.22%
Don’t Know 1.35% 5.48%
Supplier Location <.0001
Dar Es Salaam 10.81% 8.90%
Masasi town 9.46% 4.79%
Mbeya 4.05% 13.70%
Mtwara town 54.05% 12.33%
Sumbawanga 21.62% 60.27%
Qualifications
Doctor Present 9.09% 17.30% 0.14
Pharmacist Present 1.29% 2.56% 0.88
Nurse Present 77.92% 72.43% 0.45
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not diffuse as quickly. The AMFm was widely publicized
and ACTs were likely known to customers and shop-
keepers. Shops may be reluctant to stock a product that
is unfamiliar to them or has yet to be accepted by or is
unknown to current customers. Also, deeper informa-
tion on the demographics and experiences of the catch-
ment populations, such as socio-economic profiles or
the incidence of fever in the catchment, might have
better informed the demand variables. Further country
level research might also examine the role of spatial
heterogeneities of malaria risk in influencing shop level
stocking behavior.
Conclusions
Decisions to stock new pharmaceutical products in
Tanzanian ADDOs are influenced by a combination of
factors related to both market competition and customer
demand, but are particularly influenced by the behavior
of competing shops. Efforts to expand access to new
pharmaceutical products in developing country markets
could benefit from initial targeting of high profile shops
in competitive markets and wholesale suppliers to en-
courage faster product diffusion across all drug re-
tailers. Our results might be specific to AMFm ACTs,
given their subsidized nature and the previous availabil-
ity of ACTs in the public sector. Thus, future research
might follow an entirely new product in a market like
Tanzania. Studies of product diffusion in developing
country pharmaceutical markets will help inform policy
and market based strategies to maximize uptake while
minimizing time to adoption, improving access to life
saving medications.
Endnotes
aRCH clinics were used as a proxy in place of all pub-
lic health facilities as we did not have GPS coordinates
of all public health facilities. A large fraction of public
health facilities offer RCH services so this was a reason-
able approximation.
Figure 6 Probability of being an early adopter of ACTs under the AMFm by a) population, b) network degree, c) distance to nearest
competing shops and d) the number of shops within a 3km radius. Trend lines are produced using loess fitting. Points represent adopter
status of shops.
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